Literature DB >> 648565

Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease.

M H Tattersall, M Jarman, E S Newlands, L Holyhead, R A Milstead, A Weinberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 648565     DOI： 10.1016/0014-2964(78)90253-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  24 in total

Review 1.  Mass balance studies, with a focus on anticancer drugs.

Authors:  Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma.

Authors:  S Gera; E Musch; H K Osterheld; U Loos
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.

Authors:  U Loos; E Musch; M Engel; J H Hartlapp; E Hügl; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma.

Authors:  H K Osterheld; E Musch; G E von Unruh; U Loos; H Rauschecker; B J Mühlenbruch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Pharmacokinetics of high dose melphalan.

Authors:  M R Hersh; T M Ludden; J G Kuhn; W A Knight
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

Review 6.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation.

Authors:  Christa E Nath; Peter J Shaw; Kay Montgomery; John W Earl
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

8.  Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma.

Authors:  A G Bosanquet; E D Gilby
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

9.  The effect of dietary amino acids on the gastrointestinal absorption of melphalan and chlorambucil.

Authors:  C G Adair; J C McElnay
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line.

Authors:  A Canada; L Herman; K Kidd; C Robertson; D Trump
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.